Headaches and Erectile Dysfunction Medications at UTH-Kara (Togo)  

作　　者：Léhleng Agba Nyinèvi K. Anayo Hola K. Sikpa Mensah K. Guinhouya Tchilabalo M. Kpatcha Vinyo K. Kumako Damelan Kombate Komi Assogba Agnon A. Balogou Léhleng Agba;Nyinèvi K. Anayo;Hola K. Sikpa;Mensah K. Guinhouya;Tchilabalo M. Kpatcha;Vinyo K. Kumako;Damelan Kombate;Komi Assogba;Agnon A. Balogou(Neurology Department, University Teaching Hospital of Kara, University of Kara, Kara, Togo;Neurology Department, University Teaching Hospital of Campus, University of Lomé, Lomé, Togo;Urology-Andrology Department, University Teaching Hospital of Kara, University of Kara, Kara, Togo;Neurology Department, University Teaching Hospital of Sylvanus Olympio, University of Lomé, Lomé, Togo;Neurology Department, Regional Hospital of Kara, University of Kara, Kara, Togo)

机构地区：[1]Neurology Department, University Teaching Hospital of Kara, University of Kara, Kara, Togo [2]Neurology Department, University Teaching Hospital of Campus, University of Lomé, Lomé, Togo [3]Urology-Andrology Department, University Teaching Hospital of Kara, University of Kara, Kara, Togo [4]Neurology Department, University Teaching Hospital of Sylvanus Olympio, University of Lomé, Lomé, Togo [5]Neurology Department, Regional Hospital of Kara, University of Kara, Kara, Togo

出　　处：《World Journal of Neuroscience》2023年第4期228-235,共8页神经科学国际期刊（英文）

摘　　要：Introduction: Headaches are a common symptom affecting individuals worldwide, including in the tropical zone, and have been extensively studied in Togo. Phosphodiesterase-5 inhibitors, commonly prescribed for erectile dysfunction, are known to induce headaches, yet there is a lack of research on this topic in sub-Saharan Africa and Togo. Methods: A cross-sectional study conducted from February 1st to June 30th, 2023, including adult patients seeking erectile dysfunction treatment and prescribed PDE-5 inhibitors. Results: A total of 28 patients were included in the study, with an average age of 34.46 ± 7.5 years. The age group of 30 - 39 years was the most represented (53.57%). Among the participants, 67.86% had a history of chronic headaches. During the intake of PDE-5 inhibitors, 71.43% reported the onset of headaches. Among the 19 patients with chronic headaches, 68.42% developed headaches following PDE-5 inhibitor use (RR = 0.88, 95% CI: 0.55 - 1.40, p = 0.484). The characteristics of the induced headaches were similar to the patients’ pre-existing headaches in 78.95% of cases. Additional symptoms included nasal congestion (36.84%) and an urge to have a bowel movement (26.32%). Sildenafil (75.00%) and Tadalafil (25.00%) were the primarily prescribed PDE-5 inhibitors. The incidence of headaches did not significantly differ between the two groups (RR = 1.33, 95% CI: 0.67 - 2.64, p = 0.306). Treatment for the induced headaches involved self-medication with paracetamol (65.00%) and nonsteroidal anti-inflammatory drugs (NSAIDs) (35.00%). Conclusion: Headaches induced by PDE-5 inhibitors are a well-established reality, emphasizing the need for caution and warning in patients with pre-existing headache conditions, while individualized approaches are necessary to address the potential interplay between migraine medications and erectile dysfunction treatments.Introduction: Headaches are a common symptom affecting individuals worldwide, including in the tropical zone, and have been extensively studied in Togo. Phosphodiesterase-5 inhibitors, commonly prescribed for erectile dysfunction, are known to induce headaches, yet there is a lack of research on this topic in sub-Saharan Africa and Togo. Methods: A cross-sectional study conducted from February 1st to June 30th, 2023, including adult patients seeking erectile dysfunction treatment and prescribed PDE-5 inhibitors. Results: A total of 28 patients were included in the study, with an average age of 34.46 ± 7.5 years. The age group of 30 - 39 years was the most represented (53.57%). Among the participants, 67.86% had a history of chronic headaches. During the intake of PDE-5 inhibitors, 71.43% reported the onset of headaches. Among the 19 patients with chronic headaches, 68.42% developed headaches following PDE-5 inhibitor use (RR = 0.88, 95% CI: 0.55 - 1.40, p = 0.484). The characteristics of the induced headaches were similar to the patients’ pre-existing headaches in 78.95% of cases. Additional symptoms included nasal congestion (36.84%) and an urge to have a bowel movement (26.32%). Sildenafil (75.00%) and Tadalafil (25.00%) were the primarily prescribed PDE-5 inhibitors. The incidence of headaches did not significantly differ between the two groups (RR = 1.33, 95% CI: 0.67 - 2.64, p = 0.306). Treatment for the induced headaches involved self-medication with paracetamol (65.00%) and nonsteroidal anti-inflammatory drugs (NSAIDs) (35.00%). Conclusion: Headaches induced by PDE-5 inhibitors are a well-established reality, emphasizing the need for caution and warning in patients with pre-existing headache conditions, while individualized approaches are necessary to address the potential interplay between migraine medications and erectile dysfunction treatments.

关 键 词：HEADACHE Phosphodiesterase-5 Inhibitors Erectile Dysfunction TOGO Sub-Saharan Africa 

分 类 号：R73[医药卫生—肿瘤]